Lycera is developing a robust pipeline of selective, oral immunomodulators targeting novel autoimmune pathways. The company has two first-in-class programs that are rapidly advancing toward the clinic. Lycera is on track to begin clinical trials in 2013-2014 with its bioenergetics program focused on regulating the pathways that cells use to make and utilize energy.
In March 2011, Lycera announced a significant research collaboration with Merck for its RORγt program, and achieved it first milestone in December 2011. In February 2013, the company expanded its relationship with Merck with a new collaboration agreement to discover, develop and commercialize small-molecule therapies.